Efficacy and safety of SGLT2 inhibitors in Type 1 Diabetes after the introduction of an off-label use protocol for clinical practice

8 p.

Detalles Bibliográficos
Autores: Bayona Cebada, Ane, Nattero Chávez, María Lia, Alonso Díaz, Sara, Escobar Morreale, Héctor Francisco|||0000-0002-6890-1644, Luque Ramírez, Manuel
Tipo de recurso: artículo
Fecha de publicación:2019
País:España
Institución:Universidad de Alcalá (UAH)
Repositorio:e_Buah Biblioteca Digital Universidad de Alcalá
Idioma:inglés
OAI Identifier:oai:ebuah.uah.es:10017/66759
Acceso en línea:http://hdl.handle.net/10017/66759
https://dx.doi.org/10.1089/dia.2019.0316
Access Level:acceso abierto
Palabra clave:Canagliflozin
Dapagliflozin
Diabetic ketoacidosis
Empagliflozin
SGLT2 inhibitors
Type 1 diabetes mellitus
Medicina
Medicine
id ES_bafd009efd3dcfa434301f003e31b7da
oai_identifier_str oai:ebuah.uah.es:10017/66759
network_acronym_str ES
network_name_str España
repository_id_str
spelling Efficacy and safety of SGLT2 inhibitors in Type 1 Diabetes after the introduction of an off-label use protocol for clinical practiceBayona Cebada, AneNattero Chávez, María LiaAlonso Díaz, SaraEscobar Morreale, Héctor Francisco|||0000-0002-6890-1644Luque Ramírez, ManuelCanagliflozinDapagliflozinDiabetic ketoacidosisEmpagliflozinSGLT2 inhibitorsType 1 diabetes mellitusMedicinaMedicine8 p.Aims: We evaluated the real-life efficacy and safety of empagliflozin in combination with optimized insulin therapy in patients with type 1 diabetes (T1D). Methods: This was a prospective study, including 27 patients with T1D treated with insulin therapy to whom empagliflozin was added according to an off-label protocol approved for use in clinical practice. The primary end point was the change in HbA1c 52 weeks after the addition of empagliflozin to insulin therapy. Blood pressure (BP), weight, and safety were also assessed. Results: At week 52, the addition of empagliflozin significantly reduced HbA1c from 8.0% ± 0.7% to 7.2% ± 0.8% (P < 0.001). The mean percentage of time in range for capillary glucose monitoring increased from 50% to 62% (P = 0.008) in parallel to a -0.08 IU/(kg·day) reduction in insulin requirements (P = 0.031). There was also a reduction in the body weight (-8 kg) and in systolic BP from 134 to 127 mmHg (P < 0.001). The most commonly reported adverse events were genitourinary infections (10 episodes in 52 weeks of follow-up). One patient developed an episode of mild diabetic ketoacidosis that motivated empagliflozin withdrawal. No severe hypoglycemic events were registered. Conclusions: Our results suggested that the use of empagliflozin following a strict off-label protocol may represent an effective and safe option in real life among patients with T1D, improving metabolic control, and ameliorating some cardiovascular risk factors.20192019-10-23journal articlehttp://purl.org/coar/resource_type/c_6501NAhttp://purl.org/coar/version/c_be7fb7dd8ff6fe43info:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10017/66759https://dx.doi.org/10.1089/dia.2019.031631644310reponame:e_Buah Biblioteca Digital Universidad de Alcaláinstname:Universidad de Alcalá (UAH)Inglésengopen accesshttp://purl.org/coar/access_right/c_abf2Attribution-NonCommercial-NoDerivatives 4.0 Internationalhttp://creativecommons.org/licenses/by-nc-nd/4.0/info:eu-repo/semantics/openAccessoai:ebuah.uah.es:10017/667592026-06-18T11:13:07Z
dc.title.none.fl_str_mv Efficacy and safety of SGLT2 inhibitors in Type 1 Diabetes after the introduction of an off-label use protocol for clinical practice
title Efficacy and safety of SGLT2 inhibitors in Type 1 Diabetes after the introduction of an off-label use protocol for clinical practice
spellingShingle Efficacy and safety of SGLT2 inhibitors in Type 1 Diabetes after the introduction of an off-label use protocol for clinical practice
Bayona Cebada, Ane
Canagliflozin
Dapagliflozin
Diabetic ketoacidosis
Empagliflozin
SGLT2 inhibitors
Type 1 diabetes mellitus
Medicina
Medicine
title_short Efficacy and safety of SGLT2 inhibitors in Type 1 Diabetes after the introduction of an off-label use protocol for clinical practice
title_full Efficacy and safety of SGLT2 inhibitors in Type 1 Diabetes after the introduction of an off-label use protocol for clinical practice
title_fullStr Efficacy and safety of SGLT2 inhibitors in Type 1 Diabetes after the introduction of an off-label use protocol for clinical practice
title_full_unstemmed Efficacy and safety of SGLT2 inhibitors in Type 1 Diabetes after the introduction of an off-label use protocol for clinical practice
title_sort Efficacy and safety of SGLT2 inhibitors in Type 1 Diabetes after the introduction of an off-label use protocol for clinical practice
dc.creator.none.fl_str_mv Bayona Cebada, Ane
Nattero Chávez, María Lia
Alonso Díaz, Sara
Escobar Morreale, Héctor Francisco|||0000-0002-6890-1644
Luque Ramírez, Manuel
author Bayona Cebada, Ane
author_facet Bayona Cebada, Ane
Nattero Chávez, María Lia
Alonso Díaz, Sara
Escobar Morreale, Héctor Francisco|||0000-0002-6890-1644
Luque Ramírez, Manuel
author_role author
author2 Nattero Chávez, María Lia
Alonso Díaz, Sara
Escobar Morreale, Héctor Francisco|||0000-0002-6890-1644
Luque Ramírez, Manuel
author2_role author
author
author
author
dc.subject.none.fl_str_mv Canagliflozin
Dapagliflozin
Diabetic ketoacidosis
Empagliflozin
SGLT2 inhibitors
Type 1 diabetes mellitus
Medicina
Medicine
topic Canagliflozin
Dapagliflozin
Diabetic ketoacidosis
Empagliflozin
SGLT2 inhibitors
Type 1 diabetes mellitus
Medicina
Medicine
description 8 p.
publishDate 2019
dc.date.none.fl_str_mv 2019
2019-10-23
dc.type.none.fl_str_mv journal article
http://purl.org/coar/resource_type/c_6501
NA
http://purl.org/coar/version/c_be7fb7dd8ff6fe43
dc.type.openaire.fl_str_mv info:eu-repo/semantics/article
format article
dc.identifier.none.fl_str_mv http://hdl.handle.net/10017/66759
https://dx.doi.org/10.1089/dia.2019.0316
31644310
url http://hdl.handle.net/10017/66759
https://dx.doi.org/10.1089/dia.2019.0316
identifier_str_mv 31644310
dc.language.none.fl_str_mv Inglés
eng
language_invalid_str_mv Inglés
language eng
dc.rights.none.fl_str_mv open access
http://purl.org/coar/access_right/c_abf2
Attribution-NonCommercial-NoDerivatives 4.0 International
http://creativecommons.org/licenses/by-nc-nd/4.0/
dc.rights.openaire.fl_str_mv info:eu-repo/semantics/openAccess
rights_invalid_str_mv open access
http://purl.org/coar/access_right/c_abf2
Attribution-NonCommercial-NoDerivatives 4.0 International
http://creativecommons.org/licenses/by-nc-nd/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.source.none.fl_str_mv reponame:e_Buah Biblioteca Digital Universidad de Alcalá
instname:Universidad de Alcalá (UAH)
instname_str Universidad de Alcalá (UAH)
reponame_str e_Buah Biblioteca Digital Universidad de Alcalá
collection e_Buah Biblioteca Digital Universidad de Alcalá
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869417985955856384
score 15,811543

Similares en LA Referencia